MCID: PLS011
MIFTS: 56

Plasmacytoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Plasmacytoma

MalaCards integrated aliases for Plasmacytoma:

Name: Plasmacytoma 12 20 58 54 44 15 17 71
Solitary Plasmacytoma 12 20 58 32
Solitary Osseous Plasmacytoma 71
Plasmacytoma - Category 71
Myeloma - Solitary 12
Myeloma, Solitary 12
Solitary Myeloma 12

Characteristics:

Orphanet epidemiological data:

58
plasmacytoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:3721
MeSH 44 D010954
NCIt 50 C9349
SNOMED-CT 67 302852008
ICD10 32 C90.3
MESH via Orphanet 45 D010954
ICD10 via Orphanet 33 C90.2 C90.3
UMLS via Orphanet 72 C0032131
Orphanet 58 ORPHA86855
UMLS 71 C0032131 C0272256 C1532560

Summaries for Plasmacytoma

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 86855DefinitionPlasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms. There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues. Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations.Visit the Orphanet disease page for more resources.

MalaCards based summary : Plasmacytoma, also known as solitary plasmacytoma, is related to solitary osseous plasmacytoma and plasma cell neoplasm, and has symptoms including bone pain An important gene associated with Plasmacytoma is PVT1 (Pvt1 Oncogene), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Immunologic Factors and Heptavalent Pneumococcal Conjugate Vaccine have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and bone marrow, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 74 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...

Related Diseases for Plasmacytoma

Diseases related to Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 574)
# Related Disease Score Top Affiliating Genes
1 solitary osseous plasmacytoma 32.5 NCAM1 CD79A CD38 B2M
2 plasma cell neoplasm 32.1 PVT1 IL6 CD38 B2M
3 plasmablastic lymphoma 32.1 PTPRC MYC CD38
4 extramedullary plasmacytoma 32.0 IRF4 IL6 IGKC CD79A CD38 CCND1
5 myeloma, multiple 31.6 PVT1 PTPRC NCAM1 MYC IRF4 IL6
6 amyloidosis 31.2 IL6 IGKC CCND1 B2M
7 post-transplant lymphoproliferative disease 30.8 IL6 B2M
8 castleman disease 30.7 IL6ST IL6R IL6
9 osteogenic sarcoma 30.5 PVT1 MYC IL6 IL11
10 peripheral nervous system disease 30.4 PTPRC NCAM1 MYC IL6 CCND1 B2M
11 acquired immunodeficiency syndrome 30.3 MYC IL6 CD79A CD38 B2M
12 human herpesvirus 8 30.3 IL6ST IL6R IL6
13 plasma cell leukemia 30.2 NCAM1 MYC IRF4 IL6 CD38 CCND1
14 thrombocytosis 30.2 LIF IL6 IL11
15 kaposi sarcoma 30.2 OSM MYC IL6ST IL6R IL6 CCND1
16 immune deficiency disease 30.2 PTPRC IL6 CD79A CD38 B2M
17 mature t-cell and nk-cell lymphoma 30.2 NCAM1 MYC CD79A
18 b-cell lymphoma 30.1 PVT1 PTPRC PAX5 MYC IRF4 CCND1
19 monoclonal paraproteinemia 30.1 PAX5 NCAM1 CD79A
20 epiglottis neoplasm 30.1 PTPRC CD79A CCND1
21 glomeruloid hemangioma 30.0 PTPRC IL6
22 non-secretory myeloma 30.0 NCAM1 CD38 B2M
23 burkitt lymphoma 29.9 PVT1 PAX5 MYC IRF4 IL6
24 acute promyelocytic leukemia 29.9 PVT1 PTPRC NCAM1 MYC IL6 CCND1
25 reticulosarcoma 29.9 PTPRC PAX5 MYC B2M
26 marginal zone b-cell lymphoma 29.9 PAX5 IRF4 CD79A CCND1
27 leukemia 29.9 STMN1 PAX5 MYC LIF IL6ST CCND1
28 peripheral t-cell lymphoma 29.8 PTPRC NCAM1 CD38 CCND1
29 monoclonal gammopathy of uncertain significance 29.8 PTPRC NCAM1 MYC IRF4 IL6 CD38
30 lymphoma, hodgkin, classic 29.8 PVT1 PTPRC PAX5 IRF4
31 mediastinal malignant lymphoma 29.8 PAX5 CD79A
32 alpha chain disease 29.8 CD79A CCND1
33 t-cell lymphoblastic leukemia/lymphoma 29.7 PTPRC MYC IRF4 CCND1
34 lymphoma 29.7 PVT1 PTPRC PAX5 MYC IRF4 IL6
35 blood protein disease 29.7 PTPRC NCAM1 MYC IL6 CD38 B2M
36 bone lymphoma 29.6 PTPRC IRF4 CD79A
37 richter's syndrome 29.6 MYC IRF4 CD38
38 lymphoplasmacytic lymphoma 29.6 PAX5 CD79A CD38 B2M
39 inflammatory bowel disease 29.6 PTPRC MYC IL6ST IL6R IL6 IL11
40 neuroendocrine carcinoma 29.6 PTPRC PAX5 NCAM1
41 myelodysplastic syndrome 29.5 MYC IL6 IL11 CD38 B2M
42 lymphoma, mucosa-associated lymphoid type 29.5 PTPRC PAX5 MYC IRF4 IGKC CD79A
43 mantle cell lymphoma 29.5 PTPRC PAX5 MYC IL6 CCND1 B2M
44 lymphatic system disease 29.4 PTPRC MYC IRF4 CD79A CCND1
45 leukemia, acute myeloid 29.4 PTPRC PAX5 NCAM1 MYC IL6 CD79A
46 rhabdomyosarcoma 29.4 PTPRC PAX5 NCAM1 MYC CCND1
47 diffuse large b-cell lymphoma 29.3 PTPRC PAX5 MYC IRF4 IL6 CD79A
48 waldenstroem's macroglobulinemia 29.1 PTPRC PAX5 IRF4 CD38 CCND1
49 multicentric castleman disease 29.1 PAX5 IRF4 IL6 CD79A CD38
50 lymphoma, non-hodgkin, familial 28.9 PTPRC PAX5 NCAM1 MYC IRF4 IL6R

Graphical network of the top 20 diseases related to Plasmacytoma:



Diseases related to Plasmacytoma

Symptoms & Phenotypes for Plasmacytoma

UMLS symptoms related to Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Plasmacytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCND1 CD79A EBF1 IL6R IL6ST MYC

MGI Mouse Phenotypes related to Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 B2M CCND1 CD38 CD79A EBF1 IL6
2 hematopoietic system MP:0005397 10.22 B2M CCND1 CD38 CD79A EBF1 IL6
3 homeostasis/metabolism MP:0005376 10.21 B2M CCND1 CD38 CD79A IL6 IL6R
4 immune system MP:0005387 10.13 B2M CCND1 CD38 CD79A EBF1 IL6
5 endocrine/exocrine gland MP:0005379 10.09 B2M CCND1 CD38 IL6 IL6R IL6ST
6 integument MP:0010771 9.91 B2M CCND1 EBF1 IL6 IL6ST LIF
7 liver/biliary system MP:0005370 9.81 B2M CD79A EBF1 IL6 IL6R IL6ST
8 neoplasm MP:0002006 9.65 B2M CCND1 CD79A IL6 IL6R IL6ST
9 nervous system MP:0003631 9.47 B2M CCND1 CD79A EBF1 IL6 IL6R

Drugs & Therapeutics for Plasmacytoma

Drugs for Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4
2 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
3
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
4
Carmustine Approved, Investigational Phase 3 154-93-8 2578
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
8
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
9
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
10
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
11
Iron Approved Phase 3 7439-89-6 23925 29936
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
14
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
15
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
17
Pamidronate Approved Phase 3 40391-99-9 4674
18
Idarubicin Approved Phase 3 58957-92-9 42890
19
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
20
deoxycholic acid Approved Phase 3 83-44-3 222528
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Sodium citrate Approved, Investigational Phase 3 68-04-2
23
Ixazomib Approved, Investigational Phase 3 1072833-77-2
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26
Glutaral Experimental Phase 3 111-30-8 3485
27
Oblimersen Experimental, Investigational Phase 3 190977-41-4
28 Protective Agents Phase 3
29 Micronutrients Phase 3
30 Nutrients Phase 3
31 Trace Elements Phase 3
32 Neuroprotective Agents Phase 3
33 Methylprednisolone Acetate Phase 3
34 Anticoagulants Phase 3
35 Dextrans Phase 3
36 Plasma Substitutes Phase 3
37 Ferric Oxide, Saccharated Phase 3
38 Blood Substitutes Phase 3
39 Iron-Dextran Complex Phase 3
40 Antimitotic Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42
Liposomal doxorubicin Phase 3 31703
43 Anti-Bacterial Agents Phase 3
44 Hematinics Phase 3
45 Epoetin alfa Phase 3 113427-24-0
46 Tubulin Modulators Phase 3
47 Antifungal Agents Phase 3
48 Amphotericin B, deoxycholate drug combination Phase 3
49 Amebicides Phase 3
50 Antiparasitic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
2 Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
3 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
4 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
5 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
6 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
7 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
8 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
9 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
10 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
11 A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer Completed NCT00058331 Phase 3
12 Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00017602 Phase 3 dexamethasone
13 Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
14 A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma Completed NCT00432458 Phase 3 Thalidomide;zoledronic acid
15 Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma Completed NCT00064038 Phase 3 dexamethasone;lenalidomide
16 A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma Completed NCT00033332 Phase 3 dexamethasone;pamidronate disodium;thalidomide;zoledronic acid
17 A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma Completed NCT00006232 Phase 3 dexamethasone;doxorubicin hydrochloride;idarubicin;vincristine sulfate
18 A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
19 Comparative Study of Dexamethasone vs Prednisone (Both in Combination With Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma With an Additional Assessment of Dexamethasone vs no Additional Treatment as Maintenance Therapy in Non-Progressing Patients Completed NCT00002678 Phase 3 dexamethasone;melphalan;prednisone
20 A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT00049673 Phase 3 prednisone;thalidomide
21 A Randomised Controlled Trial of Adjunctive Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Renal Failure [MERIT] MyEloma Renal Impairment Trial Completed NCT00416897 Phase 3 chemotherapy;dexamethasone
22 A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma Completed NCT00008229 Phase 3 melphalan
23 A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA Completed NCT00002878 Phase 3 dexamethasone;doxorubicin hydrochloride;valspodar;vincristine sulfate
24 Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL) Completed NCT00477971 Phase 3 dexamethasone;melphalan
25 Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Recruiting NCT02544308 Phase 3 Lenalidomide;Dexamethasone
26 Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Active, not recruiting NCT02516423 Phase 3 ixazomib;lenalidomide;dexamethasone;zoledronic acid
27 Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy Unknown status NCT00389701 Phase 2 bortezomib;dexamethasone
28 A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma Unknown status NCT00004903 Phase 2 cisplatin;cyclophosphamide;cytarabine;etoposide;melphalan
29 Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma Unknown status NCT00334932 Phase 1, Phase 2 bortezomib;melphalan;pegylated liposomal doxorubicin hydrochloride
30 Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
31 A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients Unknown status NCT00438841 Phase 2 bortezomib;cyclophosphamide;dexamethasone;thalidomide
32 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
33 A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM) Unknown status NCT00742404 Phase 2 bortezomib;dexamethasone;pegylated liposomal doxorubicin hydrochloride
34 A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM) Unknown status NCT00526734 Phase 2 melphalan
35 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
36 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies in Remission From HLA Partially-Matched Related Donors Completed NCT01350245 Phase 2 Cyclophosphamide;Mycophenolate Mofetil (MMF);Tacrolimus
37 Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma Completed NCT00566098 Phase 1, Phase 2 Melphalan
38 Therapeutic Potential of Human Immune Globulin Intravenous (IGIV) in Patients With Cardiac-Associated Light Chain (AL) Amyloidosis Completed NCT00547365 Phase 1, Phase 2
39 A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma Completed NCT00317811 Phase 2 bortezomib;melphalan
40 Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis Completed NCT00089167 Phase 2 dexamethasone;melphalan;thalidomide
41 Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma Completed NCT00084747 Phase 1, Phase 2 bortezomib
42 A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM) Completed NCT00054158 Phase 2 dexamethasone;doxorubicin hydrochloride;thalidomide;vincristine sulfate
43 Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients Completed NCT00022282 Phase 2 shark cartilage extract AE-941
44 A Phase II Trial of Dexamethasone and 13-cis-Retinoic Acid as First-Line Treatment for Multiple Myeloma Completed NCT00021359 Phase 2 dexamethasone;isotretinoin
45 Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Patients With Multiple Myeloma And Primary Light Chain Amyloidosis Completed NCT00007995 Phase 2 busulfan;cyclophosphamide;melphalan
46 A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma Completed NCT00014508 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan
47 A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance Completed NCT00006219 Phase 2 clarithromycin;prasterone
48 Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma Completed NCT00006021 Phase 1, Phase 2 arsenic trioxide
49 Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma Completed NCT00006013 Phase 2 semaxanib
50 Phase II Pilot Evaluation of Infusional 8 Cl-cAMP in the Treatment of Relapsed or Refractory Multiple Myeloma Completed NCT00004902 Phase 2 tocladesine

Search NIH Clinical Center for Plasmacytoma

Cochrane evidence based reviews: plasmacytoma

Genetic Tests for Plasmacytoma

Anatomical Context for Plasmacytoma

MalaCards organs/tissues related to Plasmacytoma:

40
Bone, Thyroid, Bone Marrow, T Cells, Skin, Spleen, B Cells

Publications for Plasmacytoma

Articles related to Plasmacytoma:

(show top 50) (show all 5793)
# Title Authors PMID Year
1
Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. 54 61
20404277 2010
2
IL-6: from its discovery to clinical applications. 61 54
20410258 2010
3
IL-6 and MYC collaborate in plasma cell tumor formation in mice. 61 54
20018915 2010
4
Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. 54 61
19549820 2009
5
The 'zinc knuckle' motif of Early B cell Factor is required for transcriptional activation of B cell-specific genes. 61 54
18606452 2008
6
Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. 61 54
18648000 2008
7
Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. 61 54
18089822 2007
8
Identification of ERdj3 and OBF-1/BOB-1/OCA-B as direct targets of XBP-1 during plasma cell differentiation. 54 61
17709512 2007
9
c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. 54 61
17710161 2007
10
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. 61 54
17363561 2007
11
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. 54 61
17119059 2006
12
Myc translocations in B cell and plasma cell neoplasms. 54 61
16815105 2006
13
[Expression of B cell-specific activator protein in lymphomas]. 54 61
16185503 2005
14
Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. 61 54
15751044 2005
15
Up-date on solitary plasmacytoma and its main differences with multiple myeloma. 61 54
15812350 2005
16
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. 54 61
15735016 2005
17
RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues. 61 54
15507667 2004
18
Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. 54 61
15361869 2004
19
Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. 54 61
12612069 2003
20
The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. 54 61
12360049 2002
21
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. 61 54
12685844 2002
22
MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death. 61 54
12210141 2002
23
Bob1 (OCA-B/OBF-1) differential transactivation of the B cell-specific B29 (Ig beta) and mb-1 (Ig alpha) promoters. 54 61
11907094 2002
24
IL-6 transgenic mouse model for extraosseous plasmacytoma. 54 61
11805288 2002
25
IL-11: insights in asthma from overexpression transgenic modeling. 54 61
11590369 2001
26
Unique function for carboxyl-terminal domain of Oct-2 in Ig-secreting cells. 61 54
11591767 2001
27
No involvement of Erk/MAP kinases in IL-6-induced proliferation of a B cell hybridoma cell line. 54 61
11556393 2001
28
Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. 61 54
11170286 2001
29
Localized amyloidosis and extramedullary plasmacytoma involving the larynx of a child. 61 54
11172308 2001
30
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. 54 61
11118064 2000
31
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. 54 61
11090073 2000
32
Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. 54 61
10865979 2000
33
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. 54 61
10618400 2000
34
Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. 61 54
10570182 1999
35
Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. 54 61
10499534 1999
36
Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. 54 61
10500217 1999
37
Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas. 54 61
10535253 1999
38
Hematopoietic differentiation activity of a recombinant human interleukin-6 (IL-6) isoform resulting from alternatively spliced deletion of the second exon. 61 54
10398309 1999
39
Castleman's disease. 61 54
10655569 1999
40
Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. 61 54
9661903 1998
41
Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. 54 61
9459615 1997
42
Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. 61 54
9284811 1997
43
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. 61 54
9284817 1997
44
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. 61 54
9110979 1997
45
Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc. 54 61
9188842 1997
46
Ig/myc translocations of the plasmacytoma-prone BALB/c strain occur independently of the genetic and parental origin of the affected chromosomes 6, 12, and 15. 61 54
8946197 1996
47
Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. 61 54
8911151 1996
48
Early B-cell factor (EBF) down-regulates immunoglobulin heavy chain intron enhancer function in a plasmacytoma cell line. 54 61
8693297 1996
49
Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation. 54 61
8599834 1996
50
Production of interleukin-6 by human mast cells and basophilic cells. 61 54
8592085 1996

Variations for Plasmacytoma

Expression for Plasmacytoma

Search GEO for disease gene expression data for Plasmacytoma.

Pathways for Plasmacytoma

Pathways related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 PTPRC OSM NCAM1 MYC LIF IRF4
2
Show member pathways
13.22 OSM NCAM1 MYC LIF IRF4 IL6ST
3
Show member pathways
12.88 MYC IL6ST IL6R IL6 CCND1 B2M
4 12.77 MYC IL6ST IL6R IL6 CCND1
5
Show member pathways
12.53 MYC IRF4 IL6ST IL6R IL6
6 12.37 PTPRC PAX5 NCAM1 IRF4 IL6ST CD79A
7
Show member pathways
12.34 PTPRC MYC IRF4 CD79A
8 12.27 MYC IL6 CCND1 B2M
9
Show member pathways
12.24 IL6ST IL6R IL6 CCND1
10
Show member pathways
12.16 OSM MYC LIF IL6ST IL6R IL6
11 12.14 MYC IL6R IL6 CCND1
12 11.98 NCAM1 MYC LIF IL6 IL11
13 11.95 OSM LIF IL6ST IL6 EBF1
14 11.86 PTPRC NCAM1 IL6 IL11 CD79A CD38
15 11.85 IL6R IL6 IL11 CD38
16 11.83 PTPRC NCAM1 IL6 CD79A
17
Show member pathways
11.81 IRF4 IL6ST IL6R IL6
18
Show member pathways
11.79 IL6ST IL6R IL6
19 11.78 STMN1 MYC CCND1
20
Show member pathways
11.76 MYC IL6ST IL6R IL6
21 11.72 PTPRC NCAM1 IRF4
22 11.71 PAX5 MYC CCND1
23 11.67 PTPRC NCAM1 IRF4 IL6 CD38
24 11.49 MYC IL6R IL6 CCND1
25 11.47 IL6R IL6 IL11
26
Show member pathways
11.39 IL6ST IL6R IL6
27 11.3 MYC IL6 CCND1
28 11.28 LIF IL6 CCND1
29 11.26 IL6ST IL6R IL6
30 11.22 OSM MYC LIF IRF4 IL6R IL6
31
Show member pathways
11.2 OSM LIF IL6ST IL6R IL6 IL11
32 10.96 STMN1 OSM LIF IL6 IL11
33 10.95 OSM IL6ST CCND1
34 10.63 STMN1 CCND1

GO Terms for Plasmacytoma

Cellular components related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 OSM NCAM1 LIF IL6ST IL6R IL6
2 extracellular space GO:0005615 9.92 OSM LIF IL6ST IL6R IL6 IL11
3 external side of plasma membrane GO:0009897 9.5 PTPRC NCAM1 IL6ST IL6R IGKC CD79A
4 ciliary neurotrophic factor receptor complex GO:0070110 9.16 IL6ST IL6R
5 interleukin-6 receptor complex GO:0005896 8.8 IL6ST IL6R IL6

Biological processes related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 PAX5 OSM MYC LIF IRF4 IL6
2 immune response GO:0006955 10.03 OSM LIF IL6 IGKC B2M
3 B cell receptor signaling pathway GO:0050853 9.83 PTPRC IGKC CD79A CD38
4 immunoglobulin production GO:0002377 9.81 PTPRC IL6 IGKC
5 positive regulation of cell proliferation GO:0008284 9.81 OSM MYC LIF IL6ST IL6R IL6
6 B cell differentiation GO:0030183 9.8 PTPRC IL11 CD79A
7 interferon-gamma-mediated signaling pathway GO:0060333 9.78 NCAM1 IRF4 B2M
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 OSM LIF IL6 IL11
9 positive regulation of osteoblast differentiation GO:0045669 9.77 IL6ST IL6R IL6
10 positive regulation of T cell proliferation GO:0042102 9.76 PTPRC IL6ST IL6
11 positive regulation of MAPK cascade GO:0043410 9.73 PTPRC OSM LIF IL6R IL6 IL11
12 response to cytokine GO:0034097 9.72 IL6ST IL6R CD38
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 OSM LIF IL6ST IL6R IL6
14 positive regulation of leukocyte chemotaxis GO:0002690 9.63 IL6R IL6
15 interleukin-6-mediated signaling pathway GO:0070102 9.63 IL6ST IL6R IL6
16 positive regulation of astrocyte differentiation GO:0048711 9.62 LIF IL6ST
17 neutrophil mediated immunity GO:0002446 9.61 IL6R IL6
18 positive regulation of acute inflammatory response GO:0002675 9.61 OSM IL6ST IL6
19 leukemia inhibitory factor signaling pathway GO:0048861 9.6 LIF IL6ST
20 negative regulation of hormone secretion GO:0046888 9.58 OSM LIF IL11
21 oncostatin-M-mediated signaling pathway GO:0038165 9.57 OSM IL6ST
22 vascular endothelial growth factor production GO:0010573 9.56 IL6R IL6
23 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.54 IL6ST IL6R
24 T-helper 17 cell lineage commitment GO:0072540 9.54 IRF4 IL6R IL6
25 interleukin-11-mediated signaling pathway GO:0038154 9.51 IL6ST IL6R
26 hepatic immune response GO:0002384 9.49 IL6R IL6
27 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 PTPRC OSM LIF IL6R IL6 IL11
28 cytokine-mediated signaling pathway GO:0019221 9.28 OSM MYC LIF IRF4 IL6ST IL6R

Molecular functions related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.73 OSM LIF IL6 IL11
2 growth factor activity GO:0008083 9.71 OSM LIF IL6 IL11
3 ciliary neurotrophic factor receptor activity GO:0004897 9.37 IL6ST IL6R
4 interleukin-11 binding GO:0019970 9.32 IL6ST IL6R
5 interleukin-11 receptor activity GO:0004921 9.26 IL6ST IL6R
6 interleukin-6 binding GO:0019981 9.16 IL6ST IL6R
7 interleukin-6 receptor activity GO:0004915 8.96 IL6ST IL6R
8 interleukin-6 receptor binding GO:0005138 8.8 IL6ST IL6R IL6

Sources for Plasmacytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....